Registration is now open for the Consortium’s 2023 provider Lunch and Learn series. Click on the hyperlinked topics below to learn more and register for a session on the Colorado […]

HB22-1326: Fentanyl Accountability and Prevention Act Section 1: Legislative declaration Section 2-6: Addresses the proposed criminal penalties for unlawful possession of synthetic opiates and for unlawful manufacturing, distributing, and dispensing […]

In the final hours of the 2022 legislative session, the Colorado General Assembly passed HB22-1326, the Fentanyl Accountability and Prevention, which was signed by Governor Polis. The bill received considerable […]

Please join the Colorado Consortium’s Benzodiazepine Action Work Group for our free CME lunch and learn webinar series. Webinar topics include alternative treatments to BZDs, consequences of BZD prescribed use, […]

The 2021 session of the Colorado General Assembly ended June 8, following a packed calendar that saw the session draw to a close later than usual because of COVID-19 precautions.  […]

This Colorado Consortium for Prescription Drug Abuse Prevention’s response to joining Telligen to address high priority health issues during COVID-19 and beyond has demonstrated a high level of commitment toward […]

The Consortium is very pleased to announce the Grant Writing Assistance Program is resuming starting April 1, 2021! In 2019 and 2020, this program helped 23 organizations win a combined […]

By José Esquibel The Biden-Harris Administration has released information on the priorities of the Office of National Control Policy (ONDCP). There is recognition that the COVID-19 pandemic has exacerbated the addiction […]

By José Esquibel In early February, McKinsey & Co., a major consulting firm, finalized a settlement agreement with 43 states, the District of Columbia and three territories for its role […]